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Abstract
Background: Lupus nephritis (LN) is a frequent severe complication of Systemic Lupus Erythematosus (SLE),
especially in patients of non-Caucasian ethnicity. Induction treatment for LN consists in the combination of steroids
plus a second agent (cyclophosphamide or mycophenolate mofetil) or, as a second-line, calcineurin inhibitors or
Rituximab. Induction treatment for LN can be complicated by a series of side effects, the most severe being serious
infections. Belimumab is a fully humanized monoclonal antibody that targets soluble B lymphocyte stimulator
(BLyS), approved for treatment of serologically active SLE in addition to standard of care.
Case presentation: A young Hispanic woman was diagnosed with SLE at the age of 15. After several
immunosuppressive treatments for arthritic symptoms (high-dose steroids, mycophenolate mofetil, Rituximab,
cyclophosphamide) leading to serious complications and scarce clinical improvement, she developed severe LN.
Induction treatment with a combination of intravenous high-dose methylprednisolone and cyclophosphamide was
started but, after few days, the patient developed cryptococcal meningitis. After institution of appropriate antifungal
therapy, treatment with Tacrolimus was attempted but poorly tolerated by the patient and withdrawn. Eventually,
Belimumab was initiated off-label as a last resource to treat LN. Belimumab was well tolerated by the patient and
resulted in a rapid and marked improvement in clinical symptoms and reduction in proteinuria, serum complement
levels and anti-dsDNA titer; of note, the patient developed no infectious complications.
Conclusions: We report the case of a severe LN in a young Hispanic woman who did not respond to conventional
and second-line induction therapies, due both to intolerance and to the development of serious infectious
complications. Eventually, Belimumab was successfully added to steroids and was well tolerated by the patient,
resulting in a marked improvement in clinical and biochemical parameters. We suggest that Belimumab should be
considered as a potentially efficacious treatment in patients with LN who cannot tolerate conventional therapies.
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Background
Lupus nephritis (LN) develops in approximately one third
of Systemic Lupus Erythematosus (SLE) patients, being
most common severe lupus manifestation [1]. The fre-
quency and severity of LN is increased in patients of
non-Caucasian ethnicity [2]. Standard treatment of active
proliferative LN involves an induction phase where the use
of aggressive immunosuppression is advocated; regimens
validated by large clinical trials comprise high dose steroids
in combination with a second agent (cyclophosphamide or
mycophenolate mofetil) [3]. Also, calcineurin inhibitors
can be used as second-line treatment [4]. Although not
validated by clinical trials, Rituximab can have a role in re-
sistant cases [5]. Induction treatment for LN can be com-
plicated by a series of side effects, the most severe being
serious infections. After clinical improvement, induction
treatment is usually followed by a maintenance phase,
where usually low dose steroids plus an anti-proliferative
drug (mycophenolate mofetil or azathioprine) are used [6].
The B lymphocyte stimulator (BLyS) is a survival factor
that binds to specific receptors on B cells; BLyS inhibits
apoptosis of B cells and promotes their proliferation and
antibody production. Belimumab is a fully humanized
monoclonal antibody that targets soluble BLyS and pre-
vents BLyS from engaging its receptors on B cells. Beli-
mumab is approved for treatment of serologically active
SLE in addition to standard of care, and has been used in
maintenance treatment after rescue induction treatment
[7]; its use is not indicated in SLE complicated with LN,
mainly because the trials which validated its use lacked
inclusion of patients with renal involvement [8–10]. Re-
cently, a systematic review of the literature merging data
from large clinical trials and few case reports suggested
that Belimumab can have a positive role in the treatment
of LN [11].
Case report
We present the case of a young Hispanic woman of
Peruvian descent who was diagnosed with SLE in
September 2015 at the age of 15 in her home country.
She initially presented with arthritic symptoms and no
cutaneous involvement; serum anti-nuclear antibodies
(ANA) were positive at high titer, as were anti-double
strand DNA antibodies (anti-dsDNA), and there was a
marked reduction in serum complement fractions; a pro-
teinuria of 0,6 g per day was documented, with normal
serum creatinine. A kidney biopsy was not performed, and
the patient was treated with 4 high dose steroid pulses plus
one cyclophosphamide pulse and subsequent oral steroid
tapering, oral hydroxychloroquine and angiotensin con-
verting enzyme inhibitor. Of note, during hospitalization
she developed pneumonia which required multiple un-
specified antibiotic treatment. One month after, she was
hospitalized at the Rheumatology clinic of our Hospital for
revaluation; mycophenolate mofetil was introduced at the
dose of 1 g per day, and steroid was maintained (at the
dose of 1 mg/kg per day of prednisone). After 3 months
she developed hypertransaminasemia, which prompted
withdrawal of mycophenolate mofetil and hydroxychloro-
quine; other causes of hepatitis (namely viral and auto-
immune) were excluded by means of specific serology; of
note, low grade proteinuria persisted. In April 2016 a new
course of immunosuppressive treatment with Rituximab at
the dose of 375 mg/m2 was attempted; after the second
weekly infusion the patient developed pneumonia requir-
ing hospitalization; a CT scan of the chest showed
tree-in-bud pattern in the inferior right lobe, and a bron-
choalveolar lavage was performed, retrieving no isolates for
bacterial (including mycobacteria), viral or fungal patho-
gens. The patient was treated with empiric antibiotic
therapy and discharged after resolution of symptoms. She
was again hospitalized in July 2016 for worsening of arth-
ritic symptoms and nephrotic range proteinuria; central
nervous system involvement was excluded by means of
head MRI. SLE Activity Index (SLEDAI) was 38, a value
consistent with severe flare of SLE. The patient was again
treated with a single 300 mg cyclophosphamide intraven-
ous pulse while maintained with oral prednisone 1 mg/kg
per day; she immediately developed respiratory symptoms
consistent with bronchial infection and received treatment
with antibiotics and intravenous immunoglobulins with
benefit; cyclophosphamide was then administered orally at
1 mg/kg per day. She was once more hospitalized 1 month
after for nausea and headache; she had marked hypertran-
saminasemia, proteinuria and hematuria, with normal
kidney function; cyclophosphamide was immediately with-
drawn, and a liver biopsy showed evidence of iatrogenic
damage; meanwhile, she also received 5 plasmapheresis
treatments for the suspicion of autoimmune hepatitis. The
patient constantly maintained ANA test positivity (mea-
sured by indirect immunofluorescence) and a very high
level of anti-dsDNA (> 2000 U/ml, measured by fluor-
escent beads assay), and marked consumption of serum
complement (C3 41 mg/dl [reference range 90–180],
C4 8 mg/dl [reference range 10–40]).
In September 2016 the patient was referred to the
Nephrology unit for evaluation; physical examination was
unremarkable except for facies lunaris and leg muscle
hypotrophy related to long-time steroid use. A kidney bi-
opsy was performed for the persistence of nephrotic-range
proteinuria (proteinuria/creatininuria on a single void urine
sample 18; serum albumin 3, 5 g/dl) associated with micro-
hematuria (3+ on dipstick) and normal kidney function
(serum creatinine 0, 5 mg/dl). Histological analysis revealed
on light microscopy diffuse glomerular segmental necrosis
with crescent formation (see Fig. 1), diffuse tubular vacuoli-
zation, diffuse interstitial edema and normal small-size ar-
teries, and on immunofluorescence weak diffuse IgG, C3,
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kappa and lambda chain sub-endothelial deposits; the find-
ings were consistent with diffuse segmental proliferative LN
(class IV-S ISN-RPS classification [12]). Induction treat-
ment was initiated with the administration of three pulses
of intravenous steroid (Methylprednisolone 350 mg) and
one pulse of intravenous cyclophosphamide (500 mg). A
skin lesion in the tight was biopsied and cutaneous vascu-
litis consistent with SLE was diagnosed. Three days after
discontinuation of intravenous immunosuppressive treat-
ment, the patient developed high-grade fever with shivering
and intense headache. A lumbar puncture was performed
and liquor cultures resulted positive for Cryptococcus;
treatment with liposomal amphotericin B and fluocytosine
was initiated. After obtaining negative blood cultures initial
treatment was subsequently switched to fluconazole. For
persistence of nephrotic syndrome, after multidisciplinary
discussion, treatment with a calcineurin inhibitor (tacroli-
mus) was attempted; unfortunately, administration of this
drug resulted very poorly tolerated by the patient, who
developed acute gastrointestinal symptoms with acute
kidney injury stage 2 as per KDIGO guidelines [13], and
treatment was discontinued. Given the very poor renal and
overall prognosis for LN if left untreated, use of Belimumab
as a last resource was deemed reasonable, although
off-label. The patient was started on fortnightly Belimumab
infusion at the dose of 10 mg/kg while maintained on pred-
nisone at the dose of 12, 5 mg per day. After 1 month of
treatment, Belimumab was switched to monthly ad-
ministrations and steroid tapering was commenced.
Belimumab was well tolerated by the patients and
arthritic symptoms gradually improved; of note, the
patients remained free from infections. Kidney func-
tion remained normal, and proteinuria and hematuria
gradually decreased. Anti-dsDNA antibodies titer di-
minished rapidly and steadily; serum complement
levels (which were already starting to decline before
Belimumab initiation) normalized almost completely.
Trends of serum creatinine, proteinuria/creatininuria,
serum complement and anti-dsDNA are depicted in Fig. 2.
Presently, after 6 months of treatment with Belimumab,
the patient is asymptomatic, with a serum creatinine of 0,
5 mg/dl, a proteinuria/creatininuria on single void urine
sample of 0,87, 2+ hematuria on dipstick, C3 70 mg/dl
and C4 13 mg/dl, anti-dsDNA 134 U/ml. Measured SLE-
DAI score is 10, consistent with mild SLE activity. Consid-
ered the fair improvement of the clinical picture, a slow
steroid tapering is currently ongoing.
Discussion
Treatment of active proliferative LN can be challenging,
especially for patients who do not respond to first line
treatments or those who develop severe infectious com-
plications. In this subset of patients, substantial risk of
progression to end stage renal disease must be weighted
about the potentially fatal risk of infections. Before the
introduction of immunosuppressive therapy, the progno-
sis of LN was extremely dismal [14]. Despite the great
improvement in modern standard of care, the presence
of LN is associated with an extremely high risk of end
stage renal disease (ESRD) and still an increased risk of
death; also, the presence of renal insufficiency is linked
to lower health-related quality of life [2]. Premature ath-
erosclerosis, possibly due to the chronic inflammatory
state of SLE [15], is now recognized as one of the leading
causes of morbidity and mortality in SLE [16]. Neverthe-
less, it should be kept in mind that a substantial contri-
bution to mortality in LN patients is conferred by
serious infections [16] (especially in under-developed
countries) and active disease. Cryptococcal meningitis is
the most commonly reported invasive fungal diseases in
SLE [17, 18]; most commonly, invasive fungal infections
present early in the disease course, are associated with
Fig. 1 Kidney biopsy showing on light microscopy evidence of crescent formation in one glomerulus (left panel, PAS staining) and glomerular
segmental endocapillary proliferation (right panel, Masson Trichrome staining)
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high disease activity and high-dose steroid use, and bear
a substantial risk for fatal outcome [17]. The diagnosis
of invasive fungal infections may be complicated by the
overlap of clinical characteristics with active SLE; in our
case, the presence of meningeal symptoms was initially
attributed to possible SLE involvement of the central
nervous system; nevertheless, this last hypothesis was
rapidly discarded an appropriate diagnostic procedure
(lumbar puncture) was performed, demonstrating the
presence of fungal meningitis. After appropriate anti-
biotic treatment was instituted, in accordance with pa-
tient’s will and after discussion with her mother we
decided to insist on immunosuppressive treatment despite
complications and poor tolerance aiming at minimizing
the consistent risk of rapid progression to ESRD and of
extra-renal manifestations of SLE. Two major randomized
trials (BLISS-52 [8] and BLISS-76 [9]) validated the use of
Belimumab in addition to standard of care for the treat-
ment of active SLE; apart from demonstrating the clinical
efficacy of Belimumab versus placebo, these studies showed
that rates of serious adverse events, including infectious
complications, did not differ substantially across groups.
Moreover, post-hoc subgroup analyses of patients with LN
in the two BLISS studies indicated greater renal disease im-
provements with Belimumab than with placebo [19]. Since
data available at the moment suggested that infections do
not seem to be a major concern in patients treated with
Belimumab, and considering the available reports [20–22]
of successful treatment of LN with Belimumab and the
suggestions derived from the BLISS trials [11, 19], after re-
trieval of ethical committee approval we proceeded with
this treatment in adjunction to steroids. Belimumab is so
far well tolerated by our patients, with absence of notable
side effects or adverse events. Belimumab resulted in a
strong improvement in parameter related to disease activ-
ity and in a consistent reduction in proteinuria and micro-
hematuria. Consistent with results of previously mentioned
clinical trials [8, 9], Belimumab resulted in a fair reduction
in SLEDAI score. We hope that in the near future ongoing
clinical trials [23] can establish a clear role for Belimumab
in the treatment of LN, and better identify those patients
who may benefit the most from this treatment. Meanwhile,
we suggest that Belimumab may be used off-label in that
subset of patients with active LN who develop severe infec-
tious complications after first and second-line conventional
treatments for LN or who are intolerant to them.
Fig. 2 Trends of serum creatinine (top panel, dark-grey line), proteinuria/creatininuria (top panel, light-grey line), serum C3 (bottom panel, dark-
blue line), serum C4 (bottom panel, light-blue line), anti-dsDNA titer (bottom panel, black line) from the date of kidney biopsy over time and
through the different courses of Immunosuppressive therapies. I.v. steroid: three intravenous 500 mg methylprednisolone pulses; i.v. cyc: one
intravenous 500 mg cyclophosphamide pulse; Fk: tacrolimus; prednisone: oral tapering prednisone
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Conclusions
We report the case of a severe LN in a young Hispanic
female, who was deemed untreatable with conventional
and second-line induction therapies, due both to intoler-
ance and to the development of serious infectious compli-
cations, among which cryptococcal meningitis. Eventually,
Belimumab was successfully added to steroids and re-
sulted in a marked improvement in clinical and bio-
chemical parameters, with disappearance of arthritic
symptoms, reduction in proteinuria and microhematuria,
reduction of anti-dsDNA antibodies and normalization of
serum complement at 6 months. We suggest that
Belimumab should be considered as a potentially ef-
ficacious treatment in patients with LN who cannot
tolerate conventional therapies.
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